34 results about "Phenylbutyrate" patented technology

A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention / suppression agent.

The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.

The present invention discloses a meso-diaminopimelate dehydrogenase mutant of Proteus vulgaris and its application, belonging to the technical field of bioengineering. The present invention constructs a PvDAPDH mutant, which, compared with the wild enzyme, can catalyze the synthesis of D-amino acids from a variety of aromatic α-ketoacids, and the stereoselectivity can reach 95%. The triple mutant W121I / H227I / R181S of pvDAPDH constructed in the present invention shows good compatibility with different large-volume aromatic α-ketoacid substrates, can simultaneously catalyze the conversion of most aromatic α-ketoacid substrates into D-amino acids, shows high catalytic activity towards 2-oxo-4-phenylbutyric acid, and the yield of the product D-homophenylalanine reaches 2.1 g / L. The present invention effectively expands the toolbox for the biosynthesis of aromatic D-amino acids.

A first present invention relates to an aqueous composition including: (A) 4-phenylbutyric acid or esters thereof, or pharmacologically acceptable salts thereof, in which the aqueous composition is stored in a container of which a portion in contact with the aqueous composition is partly or wholly made of a resin containing a polyolefin. A second present invention relates to an aqueous composition including: (A) 4-phenylbutyric acid or esters thereof, or pharmacologically acceptable salts thereof; and (B) a chelating agent.

A method for treating inclusion body myositis (IBM) in a subject can include: providing a subject that has IBM; administering phenylbutyrate (PBA) to the subject in a therapeutically effective amount to provide a treatment for the IBM; obtaining at least one biological sample from the subject after initiation of the treatment for the IBM; measuring a biological indicator in the at least one biological sample, wherein the biological indicator is mitochondrial membrane potential; and monitoring a change in the biological indicator as an indication of effectiveness of the treatment.

Provided herein are pharmaceutical formulations comprising an optionally 4-substituted phenylbutyrate for improved topical application. In some embodiments, the optionally 4-substituted phenylbutyrate is present at a concentration ranging from about 1-40% by weight. The present disclosure also provides methods of preparing said pharmaceutical formulations, as well as uses and methods of treating subjects affected by inflammatory skin disorder or skin-related disease with said pharmaceutical formulations.

The present invention discloses a method for enzymatically synthesizing ethyl 2-N-benzylamino-4-phenylbutyrate, wherein ethyl 2-oxo-4-phenylbutyrate and benzylamine are used as substrates, and an asymmetric reductive amination reaction is performed by two mutants of a reductive aminase. The reaction is carried out under mild conditions, and a product is obtained by a series of treatments after the reaction. The present invention shortens the synthetic route, reduces costs, reduces material loss, has high conversion rate and high stereoselectivity, conforms to the concept of green development, provides an effective method and theoretical guidance for the synthesis of potential ACEI drugs, and determines the gene sequence and amino acid sequence of the relevant mutants.

The large-scale artificial synaptic device arrays based on the organic molecule-nanowire heterojunctions with tunable photoconductivity are proposed and demonstrated. The organic thin films of p-type 2,7-dioctyl[1]benzothieno[3,2-b][1] benzothiophene (C8-BTBT) or n-type phenyl-C61-butyric acid methyl ester (PC61BM) are used to wrap the InGaAs nanowire parallel arrays to configure two different type-I heterojunctions, respectively. Due to the difference in carrier injection, persistent negative photoconductivity (NPC) or positive photoconductivity (PPC) are achieved in these heterojunctions. The irradiation with different wavelengths (solar-blind to visible ranges) can stimulate the heterojunction devices, effectively mimicking the synaptic behaviors with two different photoconductivities. Evidently, these photosynaptic devices are illustrated with retina-like behaviors and capabilities for large-area integration, which reveals their promising potential for artificial visual systems.

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

Provided herein are methods of administering a combination of TURSO or a pharmaceutically acceptable salt thereof and 4-phenylbutyric acid (4-PBA) or a pharmaceutically acceptable salt thereof to a subject with renal impairment. Also provided are methods of treating a neurodegenerative disease in a subject with renal impairment, comprising administering a combination of TURSO or a pharmaceutically acceptable salt thereof and 4-PBA or a pharmaceutically acceptable salt thereof to the subject.

The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

The invention discloses dodecaborane salt conjugates and application thereof to boron neutron capture therapy, and belongs to the technical field of medicines. The boron neutron capture therapy conjugate IP-dodecaborane salt disclosed by the invention is synthesized by coupling 4-(p-iodophenyl) butyric acid (IP) and dodecaborane salt. 4-(p-iodophenyl) butyric acid has excellent albumin binding capacity, and can be passively targeted to tumor cells through an EPR effect after being bound with albumin, so that tumor targeted delivery of dodecaborane salt is realized, and the boron content, T / N and T / B in tumors are remarkably improved, and therefore, the conjugate has application potential as a boron neutron capture therapy drug.

The present disclosure relates generally to methods for determining whether a patient suffering from or at risk for STXBP1- or SYNGAP1-encephalopathy will benefit from treatment with phenylbutyrate compositions comprising screening the patient for mutations in STXBP1 or SYNGAP1. Also disclosed herein are methods for selecting patients at risk for developmental and epileptic encephalopathy (DEE) for treatment with compositions including phenylbutyrate.

The invention discloses a preparation method of a crude drug for inhibiting release of platelet factors, which comprises the following steps: 1) reacting 2-[4-(1, 3-dioxo-2-isoindolyl) phenyl] butyric acid with glacial acetic acid, zinc powder and hydrochloric acid at a stirring speed of 120-140 r / min to obtain a wet solid; (2) refining the wet solid product obtained in the step (1) to obtain a medicine crude product for inhibiting the release of the platelet factors; the crude drug product for inhibiting the release of the platelet factors, which is obtained by the invention, has higher purity and yield.

The invention relates to a fibroblast activated protein targeted diagnosis and treatment integrated molecular probe, and belongs to the technical field of nuclear medicine. The invention provides a fibroblast activating protein targeted diagnosis and treatment integrated molecular probe, a precursor compound of the molecular probe is composed of an FAP targeted group, a radioactive element complexed group DOTA and 4-(4-hydroxyphenyl) butyric acid, and PEG, glutamic acid and D-lysine are used as connecting arms. The precursor compound is complexed with < 68 > Ga or < 177 > Lu to obtain a high-purity PET (Polyethylene Terephthalate) imaging molecular probe < 68 > Ga-FAPI-JNU or a high-purity therapeutic molecular probe < 177 > Lu-FAPI-JNU. Researches show that < 68 > Ga-FAPI-JNU and < 177 > Lu-FAPI-JNU have better targeting property and higher target affinity, and have obvious tumor targeting uptake in tumor-bearing mice with positive expression of fibroblast activated protein.

Provided herein are pharmaceutical formulations comprising an optionally 4-substituted phenylbutyrate for improved topical application. In some embodiments, the optionally 4-substituted phenylbutyrate is present at a concentration ranging from about 1-40% by weight. The present disclosure also provides methods of preparing said pharmaceutical formulations, as well as uses and methods of treating subjects affected by inflammatory skin disorder or skin-related disease with said pharmaceutical formulations.

The present invention discloses the use of 2-amino-3-phenylbutyric acid for improving tea quality. Treatment with a 2-amino-3-phenylbutyric acid solution effectively improves tea quality, with the best effect achieved on the fifth day after spraying at a 10 nM concentration. Treatment at this concentration significantly increases tea leaves' photosynthetic efficiency, soluble sugars, and amino acids, while significantly reducing catechin content and bitterness index, contributing to the development of tea aroma, tea color, and flavor.

Provided herein are methods for treating at least one symptom of ALS in a subject having received a first dose of CYP or transporter substrate, the method comprises administering to the subject a composition comprising a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyric acid compound, monitoring the subject's reaction to the substrate, and administering a second dose of the substrate, wherein the second dose is less than the first dose.

The present invention relates to 4 -phenylbutyric acid deriva f ives, namely the compounds N- ( 4-phenylbutanoyl-D-alanine ) and / or N- ( 4-phenylbutanoyl-L-alanine ), for use in the treatment of fibrosis. The invention further relates to said 4- phenylbutyric acid derivatives for use in the treatment of in terstitial lung disease and for use in the prevention of lung cancer.

This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.

The invention discloses application of sodium 4-phenylbutyrate in a product for improving dyszoospermia of obese males, and belongs to the technical field of biological medicines. High-fat feed is adopted to construct a rat obesity model, the protection effect of 4-PBA on the reproductive function of obese rats is studied, and experimental results show that after the 4-PBA intervenes the obese rats, the testosterone content can be obviously increased, the estradiol level can be reduced, the sperm motility can be improved, the sperm malformation rate can be reduced, the spermatogenic dysfunction can be obviously relieved, and the anti-obesity effect on testis tissue morphology, testis tissue morphology, testis tissue morphology, testis tissue morphology and testis tissue morphology can be improved. The functions of supporting cell mitochondria, endoplasmic reticulum and MAM structures are obviously improved, and a new treatment strategy and a new drug target are provided for intervening and controlling obesity induced testis dyszoospermia and improving fertility of obese males.

Provided herein are methods of administering a combination of TURSO or a pharmaceutically acceptable salt thereof and 4-phenylbutyric acid (4-PBA) or a pharmaceutically acceptable salt thereof to a subject with renal impairment. Also provided are methods of treating a neurodegenerative disease in a subject with renal impairment, comprising administering a combination of TURSO or a pharmaceutically acceptable salt thereof and 4-PBA or a pharmaceutically acceptable salt thereof to the subject.

This invention relates to albumin-bound BODIPY derivatives, their preparation, and applications, belonging to the field of pharmaceutical technology. The albumin-bound BODIPY derivative of this invention couples BODIPY with the albumin-free non-covalent binder 4-(p-iodophenyl)butyric acid (IP), and can be further coupled with a boron thiol compound (BSH). 4-(p-iodophenyl)butyric acid has excellent albumin-binding ability; by utilizing the EPR effect of albumin, tumor-targeted delivery of boron-containing modules (BODIPY or BSH) can be achieved, overcoming the dependence of traditional boron drugs 4-dihydroxyboron-L-phenylalanine (BPA) on the LAT1 transporter protein, and exhibiting a certain degree of broad-spectrum targeting. Simultaneously, the fluorine-18 (…) introduced into the BODIPY structure… 18 The F) atom allows for real-time monitoring of the distribution of boron-containing drugs in vivo via PET-CT, enabling integrated diagnosis and treatment of tumors. This conjugate exhibits high safety and low toxicity, high in vitro cellular uptake, and in vivo animal distribution experiments confirming its excellent tumor targeting properties. This invention can serve as a broad-spectrum targeted boron-containing drug in integrated BNCT diagnosis and treatment.

The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

The invention relates to the technical field of organic synthesis, and provides an impurity compound of phenylbutyrin as well as a preparation method and application thereof. The preparation method of the impurity compound comprises the following steps: reacting phenylbutyric acid with 1, 3-diphenoxy-2-propanol to prepare an intermediate III; replacing the intermediate III with nitrogen and hydrogen, and reacting to obtain an intermediate IV; reacting the intermediate IV with 4-oxo-4-phenylbutyric acid overnight to prepare an intermediate V; sodium borohydride is added into the intermediate V for reduction, and the impurity compound 2-((4-phenylbutyryloxy) propane-1, 3-diyl bis (4-hydroxy-4-phenylbutyrate)) of the phenylbutyrin is obtained. According to the technical scheme, the problem that the quality control related research cannot be promoted due to the lack of effective preparation means of the newly degraded impurities in the storage stage of the phenylbutyrin is solved.

The invention belongs to the technical field of biology, and particularly relates to application of 4-phenylbutyric acid to preparation of medicine for preventing and treating ischemia reperfusion injury, the ischemia reperfusion injury is intestinal ischemia reperfusion injury, and the 4-phenylbutyric acid can be used for preventing and treating the ischemia reperfusion injury by improving the survival rate of the intestinal ischemia reperfusion injury. The 4-phenylbutyric acid can be used for preventing and treating the ischemia reperfusion injury by relieving the intestinal tissue pathological morphology injury and inflammatory factor expression induced by the intestinal ischemia reperfusion and relieving the intestinal barrier function injury induced by the intestinal ischemia reperfusion, and a novel pharmaceutical application is provided for the 4-phenylbutyric acid on the basis of the content disclosed by the invention. A new thought is provided for preventing and treating the ischemia reperfusion injury.

A first present invention relates to an aqueous composition including: (A) 4-phenylbutyric acid or esters thereof, or pharmacologically acceptable salts thereof, in which the aqueous composition is stored in a container of which a portion in contact with the aqueous composition is partly or wholly made of a resin containing a polyolefin. A second present invention relates to an aqueous composition including: (A) 4-phenylbutyric acid or esters thereof, or pharmacologically acceptable salts thereof; and (B) a chelating agent.

The invention discloses a method for synthesizing 2-N-benzylamino-4-phenyl ethyl butyrate by an enzymic method, which comprises the following steps: taking 2-oxo-4-phenyl ethyl butyrate and benzylamine as substrates, and carrying out asymmetric reductive amination reaction through two mutants of reductive aminase. The reaction is carried out under mild conditions, and a series of treatment is carried out after the reaction to obtain the product. According to the present invention, the synthesis route is shortened, the cost is reduced, the material loss is reduced, the conversion rate and the stereoselectivity are high, the green development idea is met, the effective method and the theoretical guidance are provided for the synthesis of potential ACEI drugs, and the gene sequence and the amino acid sequence of the related mutant are determined.

A polypropylene composition comprising components A), B) and C) wherein component A) is a hindered amine light stabilizer selected from the group consisting of compounds of formulae (A-I-1), (A-I-2), (A-I-3), (A-III-1) and (A-IV-1) as defined herein: component B) is a natural or synthetic hydrotalcite, component C) is a light stabilizer selected from the group consisting of 1, 3, 5-tris (3, 5-di-tert-butyl-4-hydroxybenzyl)-2, 4, 6-trimethylbenzene, ethylene bis [3, 4-b] pyridine-2, 4, 6-trimethylbenzene, ethylene bis [3, 4-b] pyridine-2, 4-b] pyridine-2, 4-b] pyridine-2, 4-b] pyridine-2, 4-b] pyridine-2, 4-b The present invention relates to a composition comprising a component A), a component B), phenolic antioxidants selected from the group consisting of 1, 3-bis (3-tert-butyl-4-hydroxyphenyl) butyrate], 1, 3, 5-tris (3, 5-di-tert-butyl-4-hydroxybenzyl)-isocyanurate and 6-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl) propoxy]-2, 4, 8, 10-tetra-tert-butyldibenzo [d, f] [1, 3, 2] dioxaphosphocycloheptane, and wherein the weight ratio of component A) to component B) is 1: 10 to 10: 1. # imgabs0 #

This disclosure relates generally to the use of phenylbutyrate compounds, such as sodium phenylbutyrate (NaPB), in the treatment, prevention, or amelioration of liver- and kidney-related conditions such as pruritis.